Pfizer: Headwinds Dissipating, New Obesity Pipeline Update Coming Soon

no_limit_picturesA difficult period for Pfizer (NYSE:PFE) might be coming to an end. The series of setbacks, such as the failures of the obesity pipeline during 2023, and the commercial underperformance that led to expectations reset with a “kitchen sink” guidance for 2024, are now behind us, and the COVID-19 franchise-led declines in revenues are finally in the rearview mirror. My share price bottom call from last year was premature, but I believe better times are ahead and that a return to growth led  ...